Wall Street analysts expect Pfizer, Inc. (NYSE:PFE) to report sales of $13.17 billion for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Pfizer’s earnings. The highest sales estimate is $13.42 billion and the lowest is $13.02 billion. Pfizer reported sales of $13.05 billion in the same quarter last year, which indicates a positive year over year growth rate of 0.9%. The company is expected to issue its next earnings results before the market opens on Tuesday, November 7th.

On average, analysts expect that Pfizer will report full year sales of $13.17 billion for the current year, with estimates ranging from $52.21 billion to $53.27 billion. For the next fiscal year, analysts expect that the firm will post sales of $53.92 billion per share, with estimates ranging from $52.81 billion to $54.78 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Pfizer.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 EPS.

A number of research analysts recently issued reports on PFE shares. ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Morgan Stanley reaffirmed a “neutral” rating and issued a $35.00 price target (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Jefferies Group LLC reaffirmed a “neutral” rating and issued a $34.00 price target on shares of Pfizer in a report on Friday, June 16th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $38.04.

Pfizer (NYSE PFE) opened at 35.99 on Thursday. The firm’s 50-day moving average is $33.78 and its 200 day moving average is $33.53. Pfizer has a 1-year low of $29.83 and a 1-year high of $36.21. The firm has a market cap of $214.05 billion, a PE ratio of 26.33 and a beta of 1.00.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/21/13-17-billion-in-sales-expected-for-pfizer-inc-pfe-this-quarter.html.

In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.

Several institutional investors have recently made changes to their positions in PFE. Asset Planning Services Ltd. raised its stake in shares of Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. raised its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Finally, Orrstown Financial Services Inc. raised its stake in shares of Pfizer by 23.0% during the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares in the last quarter. Institutional investors own 69.00% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.